Vetter Development Service: Filling your clinical development needs — now also in Chicago - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Development Service: Filling your clinical development needs — now also in Chicago


Vetter Development Service (VDS) supports your drug-development projects, from inception to market launch. Our new Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities. The Chicago site is the first to use Bosch’s new fully automated vial filler, designed specifically for early-stage, high-value biopharmaceuticals. VDS fills clinical trial materials under strict aseptic and GMP standards.

Early planning can help save costs: Together, we work with you to develop the appropriate delivery system for your drug, starting in early development. In addition to matching all components to your product’s specifications, we replicate commercial manufacturing processes in our laboratories, which can prevent surprises when your drug reaches market production. Once products reach Phase III, we provide seamless transfer to our large-scale manufacturing facilities in Europe for late-stage and commercial production. Simultaneous activities, coupled with expertise and foresight, reduce time to market. Vetter also offers support on product lifecycle management, which ideally begins in the preclinical phase and becomes an integral part of the drug development process.

Vetter Development Service provides:

  • Primary and secondary packaging development
  • Process development
  • Clinical manufacturing
  • Pharmaceutical analysis
  • Regulatory affairs services
  • Transfer to Vetter Commercial Manufacturing
  • Solutions for a faster time to market

www.vetter-pharma.com

For US inquiries please contact +1-847-581-6888 or infoUS@vetter-pharma.com.
For EU inquiries please contact +49-751-3700-0 or info@vetter-pharma.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here